Please assess the completion status of the following clinical trial:

Trial Title: The Study of Metastatic Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients must have cyto-/histologically confirmed, recurrent or metastatic adenocarcinoma of the pancreas (mPAC).~2. Patients must have no history of prior chemotherapy.~3. Patients with prior radiotherapy.~4. Patients' baseline ECOG performance status must be 2.~5. Patients' life expectancy must be 12 weeks or greater.~6. Patients' age must be 20 and 75.~7. Patients must have adequate bone marrow function.~8. Patients must have adequate liver and renal function.~9. All patients must be sign and give written informed consent.~Exclusion criteria:~1. Patients who have major abdominal surgery, radiotherapy.~2. Patients with central nervous system metastasis.~3. Patients with active infection.~4. Pregnant or breast-nursing women.~5. Patients with active cardiopulmonary disease.~6. Patients who have peripheral neuropathy \> Grade I.~7. Patients who have serious concomitant systemic disorders.~8. Patients who have other prior or concurrent malignancy.~9. Patients who are under biologic treatment for their malignancy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Statin dose titration (Type: EXPERIMENTAL): SLOG regimen:~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians.

Based on this trial design, predict the completion outcome and termination type (if applicable).